Replicor新APASL 2019年HBV高功能治愈率的分析

StephenW

Replicor to update analysis of high rates of functional cure of HBV at APASL 2019

MONTREAL, February 11, 2019 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B and D patients, today announced it will present analysis of its HBV functional cure data from the ongoing REP 401 study at the 2019 meeting of the Asian Pacific Association for the Study of the Liver (APASL) to be held February 20-24, 2019 in Manila, Philippines.

The REP 401 protocol (NCT02565719) is a randomized, controlled trial assessing the safety and efficacy of REP 2139-Mg and REP 2165-Mg when used in combination with tenofovir disoproxil fumarate (TDF) and pegylated interferon alpha 2a (peg-IFN) in patients with chronic HBeAg negative HBV infection.

Replicor’s plenary oral presentation will occur during the Autoimmune and Viral Hepatitis Symposium on February 23, 2019 and will include updated mechanistic data as well as the current follow-up analysis after removal of all treatment demonstrating further treatment is no longer required in 85% of patients completing therapy.

Replicor’s presentation from APASL 2019 will be available on the company’s website following their disclosure at the meeting at www.replicor.com/science/conference-presentations.  For further information about the 2019 APASL Meeting visit: https://apasl2019manila.org/.

StephenW

复制器更新APASL 2019年HBV高功能治愈率的分析

蒙特利尔，2019年2月11日 -  Replicor Inc.是一家私人控股的生物制药公司，目标是治疗慢性乙型和乙型肝炎患者，今天宣布将在2019年的会议上对正在进行的REP 401研究中的HBV功能治愈数据进行分析。亚太肝脏研究协会（APASL）将于2019年2月20日至24日在菲律宾马尼拉举行。

REP 401方案（NCT02565719）是一项随机对照试验，评估REP 2139-Mg和REP 2165-Mg与替诺福韦地索普西富马酸盐（TDF）和聚乙二醇化干扰素α2a（peg-IFN）联合使用时的安全性和有效性。慢性HBeAg阴性HBV感染的患者。

Replicor的全体口头报告将在2019年2月23日的自身免疫和病毒性肝炎研讨会期间进行，并将包括更新的机械数据以及去除所有治疗后的当前随访分析，证明85％的患者不再需要进一步治疗完成治疗。

复制者2019年APASL的演示文稿将在公司网站上公布后在www.replicor.com/science/conference-presentations上公布。有关2019年APASL会议的更多信息，请访问：https：//apasl2019manila.org/。

齐欢畅

齐欢畅

Replicor’s plenary oral presentation will occur during the Autoimmune and Viral Hepatitis Symposium on February 23, 2019 and will include updated mechanistic data as well as the current follow-up analysis after removal of all treatment demonstrating further treatment is no longer required in 85% of patients completing therapy.

pourvivre

good news.

灵魂不屈

请问85%的患者不再需要进一步治疗，这是什么意思？表抗转阴了？

pourvivre

回复 灵魂不屈 的帖子

达不到指南要求的治疗标准

左罗

这应该是近半月以来最值得关注的好消息了！

齐欢畅

左罗 发表于 2019-2-13 11:58
这应该是近半月以来最值得关注的好消息了！

齐欢畅

我觉得这个结果还是很不错的，看到rep公司的股票也是涨了很多，当然具体结果还不算特别好，至少未百分之百。
但联合用药，只是用了基本的几种，就有如此结果。算不错了。罗马不是一天建成的。
接下来还是关注，至少说明这个路子是可行的。